Nalaganje...
Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
BACKGROUND AND AIMS: Fasiglifam, a potent, selective novel agonist of G protein-coupled receptor 40, stimulates insulin secretion at elevated blood glucose levels in a glucose-dependent manner. This study evaluated the potential effect of hepatic impairment on the pharmacokinetics and safety of a si...
Shranjeno v:
| izdano v: | Drugs R D |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5995786/ https://ncbi.nlm.nih.gov/pubmed/29488154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-018-0229-9 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|